Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 1.00 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.47 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2046433 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL623596 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3998225 | 1.00 | — | — | |
| Maleic Acid SCHEMBL613 | 1.00 | — | — | |
| Maleic Acid SCHEMBL20487516 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2046432 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2046430 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6875 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL615 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL1331192 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025118084-A1 | EARLY BREAST CANCER DETECTION USING BLOOD-BASED METABOLOMIC PROFILING | BIOMARK CANCER SYSTEMS INC. (CA) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-117887464-A | SiGe/Si and SiO 2 Is a selective etching solution | 湖北兴福电子材料股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-115522215-A | Preparation and application of MIL-88@ CoMg electrolyzed water hydrogen evolution catalyst with foamed nickel as substrate | 蔡磊 | 2022-12-27 | — | — | CN | claimed |
| WO-2011058232-A1 | NUTRIGENETIC BIOMARKERS FOR OBESITY AND TYPE 2 DIABETES | MAS-METABOLIC ANALYTICAL SERVICES OY (FI) | 2011-05-19 | — | — | WO | claimed |
| EP-1177166-B1 | PROCESS FOR PREPARING (1R,2S,4R) -(-)-2- (2'- N,N-DIMETHYLAMINO -ETHOXY) -2- PHENYL -1,7,7-TRI- METHYL -BICYCLO 2.2.1 HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2008-02-20 | — | — | EP | claimed |
| CN-121574789-A | Fermented beverage rich in alpha-ketoglutaric acid and organic acid and preparation method thereof | 现代发酵技术研究院(山西)有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260034177-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20250360086-A1 | ENCAPSULATION METHOD AND PARTICLE | UNIV OXFORD INNOVATION LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| US-20250340592-A1 | MAMMALIAN MILK-DERIVED PEPTIDES WITH ANTIMICROBIAL ACTIVITY | MATRUBIALS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3475420-B1 | FEED COMPOSITION COMPRISING AN ACID PROTEASE | EW NUTRITION GMBH (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025118084-A1 | EARLY BREAST CANCER DETECTION USING BLOOD-BASED METABOLOMIC PROFILING | BIOMARK CANCER SYSTEMS INC. (CA) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-1298391-A | 1-[(1-substituted-4-piperidinyl) methyl]-4-piperidine derivatives, process for producing the same medicinal compositions containing the same and intermediate of these compounds | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-06-06 | — | — | CN | disclosed |
| CN-1183765-A | Phenoxyethylamine derivatives having high affinity for the 5-HT1A receptor, process for their preparation, their use as medicaments and pharmaceutical compositions containing them | SOD CONSEILS RECH APPLIC (FR) | 1998-06-03 | — | — | CN | disclosed |
| US-5382600-A | 3,3-diphenylpropylamines and pharmaceutical compositions thereof | PHARMACIA AKTIEBOLAG (SE) | 1995-01-17 | — | — | US | disclosed |
| CN-1024017-C | Middle distillate compositions with improved low temperature properties | EXXON RESEARCH ENGINEERING CO (US) | 1994-03-16 | — | — | CN | disclosed |
| CN-85104295-A | Middle distillate composition with improved cold flow | — | 1986-12-03 | — | — | CN | disclosed |
| CN-85104292-A | Middle distillate compositions having improved low temperature | — | 1986-12-03 | — | — | CN | disclosed |
| US-4107391-A | ULTRAVIOLET CURING OF A SOLVENTLESS POLYESTER OR ACRYLIC RESIN COATING | GENERAL ELECTRIC COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034177-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | EPCAM, CD44, SLC17A5 | KMT2A 3975/4885MEN1 4123/4885TSHR 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.